Pancreatic Cancer Research

ResearcherUniversité Toulouse III - Paul SabatierActive in the last 2 years

Étienne Buscail

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2040-3045; OpenAlex author ID A5069855363. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 10

  1. Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study. Co-author DOI 10.1016/j.esmogo.2025.100144↗
  2. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach. Co-author DOI 10.3390/cancers15030761↗
  3. KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence. Co-author DOI 10.1038/s41598-022-07004-x↗
  4. Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. First author DOI 10.1080/0284186x.2021.1944662↗
  5. Incidence of Venous Thromboembolism in Patients With Newly Diagnosed Pancreatic Cancer and Factors Associated With Outcomes. Co-author DOI 10.1053/j.gastro.2019.12.009↗
  6. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. First author DOI 10.1016/j.dld.2019.03.004↗
  7. CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.tranon.2019.07.009↗
  8. Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers11060852↗
  9. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Su… Co-author DOI 10.3390/cancers11111656↗
  10. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Co-author DOI 10.1016/j.canlet.2017.01.002↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. L. Chiche · 6 shared papers, 2019–2022 · strength 0.60
  2. Sandrine Dabernat · 6 shared papers, 2017–2022 · strength 0.56
  3. Christophe Laurent · 5 shared papers, 2019–2022 · strength 0.50
  4. V. Vendrely · 5 shared papers, 2017–2021 · strength 0.41
  5. Charlotte Maulat · 2 shared papers, 2019–2023 · strength 0.32
  6. Louis Buscail · 2 shared papers, 2019–2023 · strength 0.32
  7. Pierre Cordelier · 2 shared papers, 2019–2023 · strength 0.32
  8. Guillaume Le Cosquer · 1 shared paper, 2023 · strength 0.22
  9. Barbara Bournet · 1 shared paper, 2023 · strength 0.22
  10. Claudia Pouypoudat · 2 shared papers, 2019–2021 · strength 0.19
  11. Jean‐Frédéric Blanc · 2 shared papers, 2019–2021 · strength 0.19
  12. Catherine Alix‐Panabières · 2 shared papers, 2019 · strength 0.18
  13. Samuel Amintas · 1 shared paper, 2022 · strength 0.16
  14. Mario Terlizzi · 1 shared paper, 2021 · strength 0.11
  15. Fabrice Muscari · 1 shared paper, 2019 · strength 0.10
  16. Christophe Cassinotto · 1 shared paper, 2019 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.